查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1912742

一次性无菌采血管市场按类型、材质、应用和最终用户划分－2026-2032年全球预测

Disposable Sterile Blood Collection Tube Market by Type, Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年一次性无菌采血管市场价值为 4.6027 亿美元，预计到 2026 年将成长至 4.8863 亿美元，年复合成长率为 8.41%，到 2032 年将达到 8.1027 亿美元。

关键市场统计数据
基准年 2025 4.6027亿美元
预计年份：2026年 4.8863亿美元
预测年份 2032 8.1027亿美元
复合年增长率 (%) 8.41%

一次性无菌采血管概述：简要介绍材料、设计演变以及检测准确性和安全性的临床重要性

一次性无菌采血管是临床诊断和检体管理的重要组成部分，有助于确保检测流程的准确性和病人安全。材料科学、无菌生产通讯协定和人体工学设计的最新进展提高了单次使用采血管的可靠性和易用性。这些采血降低了交叉感染的风险，简化了采血流程，并可与自动化分析仪和条码系统集成，从而最大限度地减少可能影响诊断准确性的分析前变异。

材料创新、无菌製造技术的进步以及诊断自动化如何重塑产品设计、采购重点和供应商优势

技术、监管和营运等多方面因素正在推动一次性无菌采血管市场格局发生显着变化。首先，材料创新正在加速从传统玻璃向先进塑胶的过渡，先进塑胶具有更优异的抗衝击性，降低了生物危害风险，并实现了可扩展的自动化生产。同时，无菌生产流程也日趋完善，采用检验的环境控制措施和一次性生产组件，最大限度地减少颗粒物和微生物污染。

评估近期美国关税对营运和采购的影响，这些关税已经改变了供应链风险状况和筹资策略。

美国近期关税政策的变化对一次性无菌采血管的供应链动态产生了切实的影响，波及原料成本、筹资策略和库存管理。针对原料聚合物、特殊添加剂或成品一次性医用产品的关税措施可能会增加依赖国际采购的製造商的到岸成本。为此，许多供应商和医疗采购商正在重新评估其供应商组合，以降低关税波动带来的风险。具体而言，他们正寻求供应商位置多元化，并扩大区域製造地的使用。

基于全面细分的洞察，将管道类型、材质、最终用户环境和应用需求与采购和产品开发槓桿联繫起来

了解市场区隔对于使产品开发、行销和分销策略与最终用户需求保持一致至关重要。按类型划分，我们分析真空采血管和非真空采血管，这决定了它们与真空采血系统的兼容性，并影响高通量采血操作人员的使用体验。按材质，我们考察玻璃管和塑胶管，这一区别为决策提供了依据，有助于评估检体完整性、破损风险以及对特定分析方法的适用性。依最终使用者划分，我们分析血库、诊断检查室和医院的市场，重点在于采购週期、样本量需求和法律规范的差异。按应用划分，我们分析生物化学检验、血液学、分子诊断和血清学检测的市场，重点关注添加剂配方、抗凝血剂和采血管设计对检测性能和后续处理的影响。

美洲、欧洲、中东和非洲以及亚太地区的区域特征如何影响製造地的选择、监管策略和市场进入方式

区域趋势在全球医疗保健系统的製造地、监管策略和需求驱动因素方面发挥关键作用。在美洲，采购重点在于大规模机构买家、集中式分销网络以及逐步采用的自动化采血流程。这些趋势有利于能够提供规模经济、合规文件和综合服务协议的供应商。同时，欧洲、中东和非洲地区的管理体制和采购机制各不相同。先进的检查室基础设施与资源有限的环境并存，灵活的产品系列和多样化的包装规格有助于市场渗透。相较之下，亚太地区都市区的诊断现代化进程迅速推进，同时本地製造能力也在不断增强，这就要求供应商在满足全球品质标准、区域成本竞争力以及符合当地监管要求之间取得平衡。

决定一次性无菌采血管领域供应商竞争优势的关键因素包括品质系统、整合能力和服务能力。

一次性无菌采血管的竞争优势主要体现在生产品质、法规遵循和与检查室工作流程的整合等。领先的製造商将投入大量资金打造检验的无菌生产环境、实施严格的批次检测通讯协定，并对原料供应商进行资格认证，以确保产品性能的稳定性。同时，那些能够将设备生产与贴标、序列化和物流等配套服务相结合的公司，能够为那些倾向于选择能够减轻管理负担的承包解决方案的机构买家提供更有价值的提案。

为製造商和负责人提供切实可行的策略性倡议，以增强韧性、加速产品差异化并更好地与临床和采购工作流程保持一致。

产业领导者应采取切实可行的措施，重点在于增强供应链韧性、深化产品差异化以及与临床工作流程更加紧密地衔接。首先，企业应实现采购多元化，考虑区域性生产和策略联盟，以降低关税波动和运输中断带来的风险，同时透过严格的供应商筛选和库存优化来确保供应的连续性。其次，需要增加对材料科学和设计创新的投入，以提高样品稳定性、降低破损率并确保自动化相容性。此外，应优先考虑生物相容性和批次可追溯性的清晰文件记录，以满足日益严格的监管要求。

我们采用了一种严谨的混合调查方法，结合了对关键相关人员的访谈、技术文献综合和供应链分析，以获得可靠的见解。

本调查方法结合了定性和定量技术，以确保基于一手和二手证据得出切实可行的见解。一手研究包括对实验室主任、采购经理、品质保证经理和生产主管进行结构化访谈，以了解营运重点、采购週期以及与一次性无菌采血管相关的关键挑战。我们获得了关于分析设备相容性要求、特定检测方法添加剂偏好以及物流和可追溯性服务期望的第一手资讯。

本文全面分析了製造、监管和供应链选择如何共同决定血液采集装置的临床效用和采购结果。

总而言之，一次性无菌采血管面临临床需求、生产精度和供应链复杂性三者交会的挑战。随着检查室现代化和自动化程度的不断提高，材料选择、管材设计和添加剂配方变得日益重要。关税变化和贸易摩擦凸显了采购多元化和区域化生产策略的必要性，而按类型、材料、最终用户和应用进行细分则为精准的产品定位提供了明确的机会。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：一次性无菌采血管市场（按类型划分）

  • 真空管
  • 非真空管

第九章：一次性无菌采血管市场（依材料分类）

  • 玻璃管
  • 塑胶管

第十章：按应用分類的一次性无菌采血管市场

  • 生物化学
  • 血液学
  • 分子诊断
  • 血清学

第十一章：依最终用户分類的一次性无菌采血管市场

  • 血库
  • 诊断检查室
  • 医院

第十二章：按地区分類的一次性无菌采血管市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 一次性无菌采血管市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：各国一次性无菌采血管市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国一次性无菌采血管市场

第十六章 中国一次性无菌采血管市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Becton, Dickinson and Company
  • Boen Healthcare Co., Ltd.
  • Corning Incorporated
  • Greiner Bio-One International GmbH
  • Hill-Rom Holdings, Inc.
  • Nipro Corporation
  • Sarstedt AG & Co. KG
  • Sekisui Medical Co., Ltd.
  • SunTech Medical, Inc.
  • Terumo Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AE420CB13A6B

The Disposable Sterile Blood Collection Tube Market was valued at USD 460.27 million in 2025 and is projected to grow to USD 488.63 million in 2026, with a CAGR of 8.41%, reaching USD 810.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 460.27 million
Estimated Year [2026] USD 488.63 million
Forecast Year [2032] USD 810.27 million
CAGR (%) 8.41%

A concise orientation to disposable sterile blood collection tubes highlighting materials, design evolution, and clinical importance for laboratory accuracy and safety

Disposable sterile blood collection tubes serve as fundamental components in clinical diagnostics and specimen management, supporting accurate laboratory workflows and patient safety. Over recent years, advancements in materials science, sterile manufacturing protocols, and design ergonomics have elevated the reliability and usability of single-use collection devices. These tubes reduce cross-contamination risk, streamline phlebotomy procedures, and integrate with automated analyzers and barcode systems, thereby minimizing pre-analytical variability that can compromise diagnostic accuracy.

Incorporating disposability as a design principle responds to heightened infection control standards and regulatory focus on sterile medical devices. Moreover, the rising complexity of diagnostic panels has driven demand for a broader range of tube types and additives tailored to specific assays and storage conditions. Consequently, procurement teams, laboratory directors, and clinical supply chain managers increasingly evaluate blood collection tubes not only on cost-per-unit but also on compatibility with laboratory instrumentation, ease of use, and traceability features. This introduction frames the subsequent analysis by situating disposable sterile blood collection tubes at the nexus of clinical quality, operational efficiency, and regulatory compliance.

How material innovation, sterile manufacturing advances, and diagnostic automation are reshaping product design, procurement priorities, and supplier advantage

The landscape surrounding disposable sterile blood collection tubes has shifted markedly due to converging technological, regulatory, and operational forces. First, material innovation has accelerated movement away from traditional glass toward advanced plastics that offer improved break-resistance and lower biohazard risk while enabling scalable, automated production. At the same time, sterile manufacturing processes have become more sophisticated, incorporating validated environmental controls and single-use production components to minimize particulate and microbial contamination.

Parallel to material and process advancements, the clinical environment has driven demand for tubes compatible with high-throughput analyzers and multiplex molecular platforms. Laboratories are standardizing on tubes that support both pre-analytical automation and sample stability for downstream molecular diagnostics. Regulatory emphasis on device traceability and biocompatibility has led manufacturers to incorporate unique identifiers, tamper-evident seals, and standardized additive formulations. As a result, procurement decisions now weigh interoperability and lifecycle risk alongside unit price, and suppliers that offer integrated solutions-combining devices, labeling, and data capture-are positioned to capture preference in institutional buying cycles.

Assessing the operational and sourcing consequences of recent United States tariff actions that have altered supply chain risk profiles and procurement tactics

Recent tariff developments in the United States have had a tangible effect on the supply chain dynamics for disposable sterile blood collection tubes, influencing input costs, sourcing strategies, and inventory management. Tariff measures targeting raw polymers, specialty additives, or finished medical disposables can increase landed costs for manufacturers that rely on international sourcing. In response, many suppliers and healthcare purchasers have reassessed supplier portfolios to mitigate exposure to tariff volatility, seeking diversification of vendor locations and increased use of regional manufacturing hubs.

Consequently, organizations have adopted a mix of tactical and strategic responses. Tactically, procurement teams have adjusted lead times and expanded buffer inventories to absorb potential cost changes and shipment delays. Strategically, original equipment manufacturers and private-label producers have evaluated nearshoring or onshoring opportunities to reduce dependence on tariff-affected supply lines and to secure faster turnaround for critical orders. At the same time, some producers have invested in process efficiencies and value engineering to offset tariff-driven cost inflation while preserving product performance and regulatory compliance. Overall, tariffs have reinforced the importance of supply chain transparency and flexible sourcing as core components of resilience planning for diagnostic consumables.

Comprehensive segmentation-driven insights linking tube type, material, end-user environment, and application needs to procurement and product development levers

Understanding segmentation is essential to align product development, marketing, and distribution strategies with end-user needs. Based on Type, market is studied across Evacuated Tube and Non-Evacuated Tube, which defines compatibility with vacuum-based phlebotomy systems and affects ease of use for high-volume phlebotomists. Based on Material, market is studied across Glass Tube and Plastic Tube, and this distinction informs decisions about sample integrity, breakage risk, and suitability for certain analytic methods. Based on End User, market is studied across Blood Bank, Diagnostic Laboratory, and Hospital, which highlights differing procurement cycles, volume requirements, and regulatory oversight across institutional settings. Based on Application, market is studied across Biochemistry, Hematology, Molecular Diagnostics, and Serology, which underscores how additive formulations, anticoagulants, and tube design influence assay performance and downstream processing.

Taken together, these segmentation lenses reveal distinct pathways for product differentiation. Evacuated tubes that pair with automation and barcoding workflows typically appeal to high-throughput diagnostic laboratories, while non-evacuated tubes may retain strength in point-of-care or small-clinic settings that prioritize simplicity and cost. Plastic tubes offer durability and safety benefits for hospitals and blood banks, whereas certain biochemical assays continue to prefer glass for compatibility with specific analyte stability profiles. For molecular diagnostics and specialized serology testing, validated additive formulations and strict lot-to-lot consistency become decisive selection criteria, prompting suppliers to emphasize quality systems and traceability in their value propositions.

How distinct regional forces across the Americas, Europe Middle East and Africa, and Asia-Pacific dictate manufacturing choices, regulatory strategy, and go-to-market approaches

Regional dynamics play a crucial role in shaping manufacturing footprints, regulatory strategies, and demand drivers across global healthcare systems. In the Americas, procurement emphasizes large institutional buyers, centralized distribution networks, and gradual adoption of automated phlebotomy workflows; these patterns favor suppliers that can deliver scale, compliance documentation, and integrated service agreements. Meanwhile, Europe, Middle East & Africa exhibits diverse regulatory regimes and procurement mechanisms; pockets of advanced laboratory infrastructure coexist with resource-constrained settings, so flexible product portfolios and variable pack sizes support market penetration. In contrast, Asia-Pacific presents a mix of rapid diagnostic modernization in urban centers and growing local manufacturing capacity, prompting suppliers to balance global quality standards with regional cost competitiveness and localized regulatory registrations.

These regional distinctions influence decisions from facility placement to regulatory dossiers and sales strategy. For example, manufacturers targeting hospital systems in the Americas may prioritize contracting capabilities and after-sales logistics, whereas success in Europe, Middle East & Africa often requires tailored regulatory pathways and partnerships to reach decentralized public health procurement. In Asia-Pacific, partnering with local distributors and aligning product specifications to regional laboratory practices accelerate adoption, particularly where in-country production reduces tariff exposure and shortens lead times. Ultimately, a regionally nuanced approach yields better alignment with buyer expectations and resiliency against supply chain disruptions.

Key supplier characteristics that determine competitive advantage in the disposable sterile blood collection tube arena including quality systems, integration, and service capabilities

Competitive dynamics in disposable sterile blood collection tubes center on manufacturing quality, regulatory compliance, and the ability to integrate with laboratory workflows. Leading manufacturers invest heavily in validated sterile production environments, stringent lot-testing protocols, and supplier qualification for raw materials to ensure consistent product performance. In parallel, firms that combine device production with complementary services-such as labeling, serialization, and logistics-create stronger value propositions for institutional purchasers who prefer turnkey solutions that reduce administrative burden.

Moreover, strategic differentiation increasingly relies on demonstrable compatibility with automation and digital tracking systems, as well as the capacity to support specialized applications like molecular diagnostics. Companies that maintain broad distribution networks and strong relationships with hospital procurement teams gain advantages in contract negotiations and rollout speed. At the same time, emerging players often focus on niche segments-such as cost-optimized plastic tube lines for resource-limited settings or premium formulations tailored to advanced serology-to carve out defensible positions. Overall, competition rewards firms that can combine product reliability, regulatory clarity, and service depth while remaining responsive to evolving clinical requirements.

Practical strategic moves for manufacturers and buyers to build resilience, accelerate product differentiation, and align offerings more closely with clinical and procurement workflows

Actionable steps for industry leaders should focus on strengthening supply chain resilience, deepening product differentiation, and forging closer ties to clinical workflows. First, companies should diversify sourcing and consider regional manufacturing or strategic partnerships to reduce exposure to tariff swings and shipping disruptions, while simultaneously implementing rigorous supplier qualification and inventory optimization to maintain continuity. Second, invest in material science and design innovations that improve sample stability, reduce breakage, and ensure compatibility with automation; prioritize clear documentation of biocompatibility and lot traceability to meet tightening regulatory expectations.

Third, align commercial models to end-user workflows by offering integrated solutions-packaging, labeling, and data capture services-that simplify procurement and reduce the burden on hospital supply chains. Fourth, expand clinical engagement through field validation studies and clinician education to demonstrate how tube selection affects assay outcomes and laboratory efficiency. Finally, deploy targeted pricing and contract structures that reflect total cost of ownership rather than unit price alone, thereby enabling longer-term partnerships that support volume stability and continuous improvement initiatives.

A rigorous mixed-methods research approach combining primary stakeholder interviews, technical literature synthesis, and supply chain analysis to ensure credible insights

The research approach combined qualitative and quantitative methods to ensure robust, actionable findings grounded in primary and secondary evidence. Primary engagement included structured interviews with laboratory directors, procurement managers, quality assurance leads, and manufacturing executives to capture operational priorities, procurement cycles, and key pain points related to disposable sterile blood collection tubes. These conversations offered direct insight into compatibility requirements with analyzers, additive preferences for specific assays, and service expectations around logistics and traceability.

Secondary analysis synthesized regulatory guidance documents, manufacturing standards, and peer-reviewed literature on specimen handling and pre-analytical variables to validate technical assertions. Supply chain mapping and trade policy reviews provided context for sourcing risks and tariff impacts. Data triangulation across multiple sources supported consistent interpretation, while sensitivity checks ensured that conclusions emphasized operational and strategic implications rather than speculative projections. Throughout the process, adherence to ethical interviewing protocols and data verification strengthened the integrity of the research outputs.

Concluding synthesis of how manufacturing, regulatory, and supply chain choices converge to determine clinical utility and procurement outcomes for blood collection devices

In summary, disposable sterile blood collection tubes sit at an intersection of clinical necessity, manufacturing precision, and supply chain complexity. Material choices, tube design, and additive formulations now carry greater weight as laboratories modernize and automation becomes more prevalent. Tariff changes and trade frictions have underscored the need for diversified sourcing and regional manufacturing strategies, while segmentation across type, material, end user, and application reveals clear opportunities for targeted product positioning.

Companies that excel will pair high-quality manufacturing controls with services that reduce administrative burden for buyers and demonstrate measurable compatibility with diagnostic workflows. By proactively addressing regulatory documentation, supply chain transparency, and clinical validation, manufacturers and purchasers can enhance resilience and improve patient safety outcomes. The conclusion is straightforward: deliberate investments in quality systems, strategic sourcing, and workflow integration will deliver the operational and clinical benefits that healthcare institutions increasingly demand.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Disposable Sterile Blood Collection Tube Market, by Type

  • 8.1. Evacuated Tube
  • 8.2. Non-Evacuated Tube

9. Disposable Sterile Blood Collection Tube Market, by Material

  • 9.1. Glass Tube
  • 9.2. Plastic Tube

10. Disposable Sterile Blood Collection Tube Market, by Application

  • 10.1. Biochemistry
  • 10.2. Hematology
  • 10.3. Molecular Diagnostics
  • 10.4. Serology

11. Disposable Sterile Blood Collection Tube Market, by End User

  • 11.1. Blood Bank
  • 11.2. Diagnostic Laboratory
  • 11.3. Hospital

12. Disposable Sterile Blood Collection Tube Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Disposable Sterile Blood Collection Tube Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Disposable Sterile Blood Collection Tube Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Disposable Sterile Blood Collection Tube Market

16. China Disposable Sterile Blood Collection Tube Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Becton, Dickinson and Company
  • 17.6. Boen Healthcare Co., Ltd.
  • 17.7. Corning Incorporated
  • 17.8. Greiner Bio-One International GmbH
  • 17.9. Hill-Rom Holdings, Inc.
  • 17.10. Nipro Corporation
  • 17.11. Sarstedt AG & Co. KG
  • 17.12. Sekisui Medical Co., Ltd.
  • 17.13. SunTech Medical, Inc.
  • 17.14. Terumo Corporation
  • 17.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY EVACUATED TUBE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY EVACUATED TUBE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY EVACUATED TUBE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY NON-EVACUATED TUBE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY NON-EVACUATED TUBE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY NON-EVACUATED TUBE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GLASS TUBE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GLASS TUBE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GLASS TUBE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY PLASTIC TUBE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY PLASTIC TUBE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY PLASTIC TUBE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BIOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BIOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BIOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BLOOD BANK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BLOOD BANK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BLOOD BANK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)